ChemotherapyFDA-approvedneoadjuvant
mFOLFOXIRI
Generic name: irinotecan
How it works
Inhibits topoisomerase I, an enzyme involved in DNA replication, causing cancer cells to die.
Cancer types
Efficacy
Studies show that mFOLFOXIRI can improve pathological complete response rates in patients with stage III colorectal cancer compared to FOLFOX.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Adagrasib in Combination with Cetuximab and Irinotecan for Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing a New Treatment for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Irinotecan Efficacy in Second-Line Lung Cancer Treatment | Lung Cancer | phase-2 | The patient's median progression-free survival was 3.8 (3.4-4.4) months, and median overall survival was 8.1 (6.5-10.9) months. | Source → |
| Combining Metformin and Irinotecan for Refractory Colorectal Cancer | Colorectal Cancer | phase-2 | The disease control rate was 41% at 12 weeks. | Source → |
| Combining Cetuximab with Chemotherapy for Liver Cancer | Colorectal Cancer | phase-2 | The rate of no evidence of disease achieved was 70.1% in the cetuximab group and 41.2% in the control group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.